In vitro immunogenic and immunostimulatory effects of zwitterionized 23-valent pneumococcal polysaccharide vaccine compared with nonzwitterionized vaccine. by Abdulamir, Ahmed Sahib et al.
In vitro immunogenic and immunostimulatory effects of zwitterionized 23-valent 
pneumococcal polysaccharide vaccine compared with nonzwitterionized vaccine. 
ABSTRACT 
Background: It was hypothesized that the observed slight immunostimulatory effect of the 
23-valent pneumococcal polysaccharide (pneumo-23) vaccine might be due to the presence 
of low levels of zwitterionic motifs. Therefore, it was hypothesized further that introducing 
zwitterionic motifs experimentally into polysaccharides of pneumo-23 vaccine might render 
it an effective immunostimulatory agent. Objective: This study was conducted to assess the in 
vitro immunostimulatory effect of zwitterionized pneumo-23 (Z-P23) vaccine compared with 
the nonzwitterionized commercial pneumo-23 (C-P23) vaccine. Methods: In vitro 
proliferation, ELISA-based in vitro cytokine synthesis (interleukin [IL]-2, interferon [IFN]-γ, 
and IL-10), and immunofluorescence microscopy-based immune cell profiling (CD4+, 
CD8+, and CD21+ cells) assays were used to evaluate the immunostimulatory effect of Z-
P23 on peripheral blood mononuclear cells (PBMC) of immunosuppressed cancer (IC) 
patients and healthy control subjects in comparison with PBMC exposed to C-P23, 
concanavalin A (positive control), and phosphate-buffered saline (PBS) (negative control). 
Results: Z-P23 induced proliferation of PBMC in the IC (81.1%) and control (75.1%) groups 
significantly higher than that achieved with concanavalin A in the IC group (51.0%; P = 0.01) 
but not in the control group (89.2%; P = NS). This was also significantly higher than that 
achieved with C-P23 in the IC (4.8%; P < 0.001) and control (6.2%; P < 0.001) groups. Z-
P23 induced IL-2 and IFN-γ synthesis in the IC group (0.61 and 0.45 ng/mL, respectively) 
significantly more than that with C-P23 (0.4 and 0.45 ng/mL; P = 0.002 and P <0.001), 
concanavalin A (0.45 and 0.31 ng/mL; P = 0.021 and P = 0.03), and PBS (0.41 and 0.29 
ng/mL; P = 0.005 and P = 0.04) but not the control group. Z-P23 induced expansion of 
CD4+, CD8+, and CD21+ lymphocytes (39.3%, 42.7%, and 8.1%, respectively) in the IC 
group higher than that with C-P23 (28.3%, 30.1%, and 5.5%; P = 0.01, P = 0.003, and P = 
NS), concanavalin A (27.2%, 35.8%, and 4.1%; P = 0.02, P = 0.048, and P = 0.035), and PBS 
(25.6%, 31.9%, and 4.2%; P = 0.018, P = 0.02, and P = 0.045). Conclusion: The in vitro 
immunostimulatory potential of Z-P23 was clearly observed on PBMC of IC patients as well 
as, to a lesser extent, healthy control subjects, stimulating the synthesis of core cytokines of 
T-helper 1, and primarily inducing CD4+ and CD8+T cells. 
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